Articles in the Category ”Applications”

FabALACTICA® in a Quantitative IgG1 Clone Profiling

September 23, 2021 | Applications, References |

Our immune system protects us from pathogens and various diseases, and the immune response is dependent on a person’s repertoire of immune cells, antibodies and circulating plasma proteins. A detailed characterization of these plasma components is important for the understanding of how they affect each individual’s immune response.
Read more »

FabRICATOR® in a DAR Analysis of Antibody-Oligonucleotide Conjugates

September 16, 2021 | Applications, References |

In this paper, scientists at Spectroswiss and Orion Pharma present a novel strategy for DAR analysis of structurally complex antibody-oligonucleotide conjugates using SmartEnzymes™ and a proteoform integration approach combined with native SEC-Orbitrap FTMS.
 
Read more »

FabRICATOR in a Comprehensive Characterization of a Bispecific Antibody

September 9, 2021 | Applications, References |

Scientists at University of Geneva and Centre d’Immunologie Pierre-Fabre here describes a comprehensive intact and middle-level characterization of a commercial bispecific antibody by using a variety of orthogonal chromatographic methods coupled to MS.
 
Read more »

GingisREX® in a Bottom-Up Analysis of Histones


Bottom-up mass spectrometry where the intact protein is digested into smaller peptides is an indispensable tool for proteomics and the studying of histone codes. Since histones are enriched with the basic amino acids arginine and lysine, enzymatic digestion is often challenging as peptides too short for LC retention and PTM localization are generated. In addition, the complex workflow entails that the combination of samples preparation, data acquisition and analysis provides a different image of the histone code.

 

Read more »

NEW TransGLYCIT™ Glycoforms Available!


Genovis launches new glycoforms with TransGLYCIT™ – A platform to create IgG with defined glycan profiles!

 

TransGLYCIT enables specific IgG N-glycan remodeling and prepares antibodies with a defined and homogenous G0, G1, G2 or G2S2 glycoform using fast and robust enzymatic workflows. With the optional FucosEXO™ 16 enzyme, afucosylated antibodies can be obtained that enable direct comparison of antibodies with or without the core fucose.

 

Read more »

Purification of Antibody Fragments via Hydrophobic Interactions


The importance of monoclonal antibodies (mAbs) as therapeutic agents is steadily increasing, and each year nearly 300 novel mAbs are being evaluated for their therapeutic effectivity. Interest has also been expressed in the use of antibody fragments as therapeutic agents. The physiochemical properties of the fragments differ significantly from that of intact antibodies, and the fragments can more easily be coupled to dyes, toxins and vesicles for diagnostic purposes, cancer therapy and improved drug delivery, respectively.
Read more »

Analytical Methods to Monitor Site-Specific ADC Generation with GlyCLICK®


Scientists at the University of Strasbourg and University of Geneva use innovative native MS and IM methodologies for analytical characterization of a site-specific ADC generated with the GlyCLICK technology.

 

Antibody-drug conjugates (ADCs) combine the benefits of tumor-targeting monoclonal antibodies with the cytotoxic effect of drug payloads covalently linked to the antibody. The ADC generation process has evolved from non-selective and uncontrolled conjugation in early generation products, to site-specific conjugation resulting in homogenous and well-defined ADCs. Conjugation at the antibody Fc glycan sites using the GlyCLICK technology has proven to be an attractive option for the generation of site-specific ADCs.
Read more »

Middle-up Analysis of Monoclonal Antibodies using FabRICATOR®


With their molecular specificity for biological targets, monoclonal antibodies (mAbs) have revolutionized the field of research and medicine. Due to numerous post-translational modifications causing heterogeneity in the structure of mAbs, a comprehensive characterization of the physiochemical properties is necessary to ensure the quality, efficacy and safety of mAb-based therapeutic drugs.
Read more »

IgG Proteases for Gene Therapy Applications

June 16, 2021 | Applications |

The development and successful commercialization of gene therapy technologies as new treatments have spurred great interest and investments in this field of research. Many challenges remain to be solved to establish gene therapy as a mainstream line of treatment, but there are currently many promising and life-changing gene therapy programs in preclinical and clinical development. Preexisting antibodies against the capsid of adeno-associated virus (AAV) vectors is a major challenge for many gene therapies that could block uptake and limit the transduction of the new genetic material. The anti-AAV antibodies are prevalent both in humans and preclinical disease models. In patient populations, up to 50% of the patients could be excluded from treatment due to high titers of anti-AAV antibodies. Several strategies are explored to reduce the antibody response, once such is enzymatic pretreatment using IgG-specific proteases.
Read more »

FabALACTICA Facilitates the Structural Insight into SARS-CoV-2 Neutralizing Antibodies


The first steps of infection with SARS-CoV-2 is binding of a viral Spike protein to a host receptor angiotensin-converting enzyme 2 (ACE2), followed by fusion of viral and host membranes. Antibodies that block this interaction are emerging as early COVID-19 therapies, however, the neutralization potencies of the antibodies are less studied.
Read more »